Temperature Management After Cardiac Arrest - Advisory Statement

This is an Advisory Statement by the Advanced Life Support Task Force of the International Liaison Committee on Resuscitation and the American Heart Association Emergency Cardiovascular Care Committee and the Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation

For more than a decade, mild induced hypothermia (32°C–34°C) has been standard of care for patients remaining comatose after resuscitation from out-of-hospital cardiac arrest with an initial shockable rhythm, and this has been extrapolated to survivors of cardiac arrest with initially non-shockable rhythms and to patients with in-hospital cardiac arrest.

Two randomized trials published in 2002 reported survival and neurologic benefit with mild-induced hypothermia. One recent randomized trial reported similar outcomes in patients treated with targeted temperature management at either 33°C or 36°C.

In response to these new data, the International Liaison Committee on Resuscitation (ILCOR) Advanced Life Support (ALS) Task Force performed a systematic review to evaluate 3 key questions:

(1) Should mild induced hypothermia (or some form of targeted temperature management) be used in comatose post-cardiac arrest patients?

(2) If used, what is the ideal timing of the intervention?

(3) If used, what is the ideal duration of the intervention?

The task force used Grading of Recommendations Assessment, Development and Evaluation methodology to assess and summarize the evidence and to provide a consensus on science statement and treatment recommendations. The task force recommends targeted temperature management for adults with out-of-hospital cardiac arrest with an initial shockable rhythm at a constant temperature between 32°C and 36°C for at least 24 hours. Similar suggestions are made for out-of-hospital cardiac arrest with a non-shockable rhythm and in-hospital cardiac arrest. The task force recommends against prehospital cooling with rapid infusion of large volumes of cold intravenous fluid. Additional and specific recommendations are provided in the document.

 

CIR.0000000000000313

 

SOURCE

Comments are closed.